Lipodystrophy Syndromes and Metabolic Disorders

Lipodystrophy syndromes are a heterogeneous group of rare disorders characterised by selective depletion of adipose tissue. Generalised forms involve near-complete absence of fat, whereas partial variants affect specific regions such as extremities or the trunk. Loss of functional adipocytes leads to ectopic lipid deposition, insulin resistance and a severe metabolic phenotype including hypertriglyceridaemia, steatohepatitis and early-onset type 2 diabetes. Underlying causes range from monogenic mutations affecting adipocyte differentiation and lipid droplet formation to acquired autoimmune or inflammatory processes. Key pathogenic mechanisms include impaired leptin and adiponectin production, aberrant activation of peroxisome proliferator-activated receptor γ, and dysregulation of pathways for lipid storage and release. Clinically, patients present with metabolic dysregulation, non-alcoholic fatty liver disease, cardiovascular complications and reproductive dysfunction. Advances in genetic sequencing, cellular imaging and biomarker profiling have enhanced diagnostic precision and enabled stratified therapeutic approaches. Lifespan and quality of life can be improved by targeted interventions such as leptin replacement, insulin sensitisation and, in select cases, gene-based or cell-based therapies. Ongoing research aims to integrate molecular understanding with novel pharmacological modalities to reduce disease burden and guide personalised management.

Research from Nature Portfolio

Recent systematic analyses have evaluated genotype-stratified therapies in monogenic insulin resistance, encompassing congenital and familial lipodystrophy subtypes. Evidence indicates that metreleptin replacement consistently lowers triglycerides and glycosylated haemoglobin across both partial and generalised forms of the disease, with greater efficacy observed in cohorts harbouring LMNA and BSCL2 mutations. Thiazolidinediones show selective benefits on lipid and glycaemic indices in PPARG and LMNA-related lipodystrophy, while recombinant human IGF-1 appears to improve glycaemic control in insulin receptor-related cases. Although the overall quality of evidence remains modest due to small sample sizes and non-randomised designs, these findings underscore the value of tailoring treatments to genetic aetiology and pave the way for more rigorous clinical trials.

Lipodystrophy Syndromes and Metabolic Disorders publication trend

The graph below shows the total number of articles in lipodystrophy syndromes and metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Adipocyte: A specialised cell that stores energy as lipid droplets, regulating systemic metabolism through endocrine signalling.

Leptin: An adipocyte-derived hormone essential for appetite regulation and metabolic homeostasis, deficient in many lipodystrophy syndromes.

Metreleptin: A recombinant human leptin analogue used as hormone replacement therapy to improve metabolic and hepatic parameters in lipodystrophy.

Hypertriglyceridaemia: An excess of triglycerides in the bloodstream, often leading to pancreatitis and cardiovascular risk in lipodystrophy.

Insulin resistance: A state in which peripheral tissues exhibit a reduced response to insulin, contributing to hyperglycaemia and dyslipidaemia.

References

1. Genotype-stratified treatment for monogenic insulin resistance: a systematic review. Communications Medicine (2023).
2. Clinical and imaging features of women with polygenic partial lipodystrophy: a case series. Nutrition & Diabetes (2024).
3. Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review. Cells (2023).
4. Molecular and Cellular Bases of Lipodystrophy Syndromes. Frontiers in Endocrinology (2022).